Cite
HARVARD Citation
Guo, C. et al. (2020). Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet oncology. 21 (11), pp. 1478-1488. [Online].